Active Filter(s):
Details:
ProLectin-M (galactomannan) is a precise chemistry based molecule that binds to galectin like receptors on the N terminal of S1 subunit of the Sars-CoV2 virus. It is being evaluated for the treatment of COVID-19.
Lead Product(s): Galactomannan
Therapeutic Area: Infections and Infectious Diseases Product Name: Prolectin-M
Highest Development Status: Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 21, 2024
Details:
ProLectin-M (galactomannan) is a chewable polysaccharide tablet for the treatment of mild to moderate and early stage COVID-19 Patients. The trial’s objective is to provide guidance for a 408 patient Phase III trial.
Lead Product(s): Galactomannan
Therapeutic Area: Infections and Infectious Diseases Product Name: ProLectin-M
Highest Development Status: Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 24, 2023
Details:
ProLectin-M (galactomannan) is a chewable polysaccharide tablet for the treatment of mild to moderate and early stage COVID-19 Patients. The trial’s objective is to provide guidance for a 408 patient Phase III trial.
Lead Product(s): Galactomannan
Therapeutic Area: Infections and Infectious Diseases Product Name: ProLectin-M
Highest Development Status: Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator: Alke Research Private Limited
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 08, 2023
Details:
The proceeds will help to start the dosage optimization study for mild to moderate COVID-19, which has already received the regulatory approval to proceed with dosing of ProLectin-M, an oral galectin antagonist that prevents the entry of the SARS-CoV-2 virus into human cells.
Lead Product(s): Galactomannan
Therapeutic Area: Infections and Infectious Diseases Product Name: ProLectin M
Highest Development Status: Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator: Triton Funds
Deal Size: $0.5 million Upfront Cash: Undisclosed
Deal Type: Financing June 12, 2023
Details:
BXT-25 is a intravenous version of hyperbaric oxygen treatment that lasts 9-18 hours and without any harmful side effects. It is a new paradigm in the way strokes and neurodegenerative diseases such as alzheimer’s, dementia, and traumatic brain injury are treated.
Lead Product(s): BXT-25
Therapeutic Area: Neurology Product Name: BXT-25
Highest Development Status: Preclinical Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 19, 2023
Details:
ProLectin-I binds to the ‘galectin fold’ of the spike protein thereby neutralizing a replication and ability of virus to infect other cells, it also binds to spike protein fragments thought to be the cause of ongoing inflammation. It is expected to treat Long COVID and IPF.
Lead Product(s): ProLectin-I
Therapeutic Area: Infections and Infectious Diseases Product Name: ProLectin-I
Highest Development Status: Phase I Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 06, 2023
Details:
ProLectin-M having galactomannan, is a new class of antiviral drug designed to antagonize galectins implicated in inflammatory, fibrotic, and malignant diseases.
Lead Product(s): Galactomannan
Therapeutic Area: Infections and Infectious Diseases Product Name: ProLectin-M
Highest Development Status: Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 08, 2022
Details:
The study shows direct binding of galectin-1 to the influenza virus, and intranasal treatment of galectin-1 could also enhance survival by reducing viral load, inflammation, and lung apoptosis.
Lead Product(s): BXT-10
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Preclinical Product Type: Undisclosed
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 31, 2020
Details:
Bioxytran seeks to explore collaborations with international drug makers to treat patients at the end stage of Acute Respiratory Distress Syndrome affected with Wuhan Coronavirus.
Lead Product(s): BXT-25
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: Undisclosed
Highest Development Status: Undisclosed Product Type: Small molecule
Partner/Sponsor/Collaborator: Undisclosed
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership February 05, 2020